12:47 PM EST, 01/10/2025 (MT Newswires) -- Insmed ( INSM ) said Friday said it expects to report full-year 2024 global net product sales of its drug Arikayce of $363.7 million, up 19% year over year.
The results are preliminary and subject to adjustment, the company said. Insmed ( INSM ) expects to report its actual results in late February.
Analysts polled by FactSet expect $356.8 million in full-year revenue.
Price: 65.21, Change: -0.51, Percent Change: -0.78